活体供肝移植治疗不可切除结直肠癌肝转移的受者与供者结局
这项前瞻性队列研究纳入3个北美中心的91例评估患者,其中10例(11%)接受活体供肝移植(LDLT)。移植后1.5年无复发生存率和总生存率分别为62%和100%。围术期并发症发生率与既定标准一致,提示经过选择的不可切除、局限于肝脏的结直肠癌肝转移患者可能从全肝切除加LDLT中获益。
要点
- 91例评估患者中10例(11%)接受LDLT,受者中位年龄45岁,供者中位年龄40.5岁。
- LDLT后1.5年无复发生存率为62%,总生存率为100%。
- 受者和供者围术期并发症发生率与既定标准一致。
核心结论
- 研究结果表明,经过选择的不可切除、局限于肝脏的结直肠癌肝转移患者可能从全肝切除加活体供肝移植中获益。
研究设计与样本
- 前瞻性队列研究,纳入3个北美肝移植中心(美国2个、加拿大1个)已建立LDLT项目的中心,共评估91例患者,其中10例(11%)接受LDLT,移植时间为2017年7月至2020年10月,随访至2021年5月1日。
主要发现
- 91例评估患者中10例(11%)接受LDLT(6例[60%]男性;中位年龄45岁[范围35-58岁])。
- 10例活体供者中7例(70%)为男性,中位年龄40.5岁(范围27-50岁)。
- LDLT后1.5年Kaplan-Meier估计的无复发生存率为62%,总生存率为100%。
- 受者Clavien-Dindo并发症:3例(30%)无并发症,3例(30%)为II级,4例(40%)为III级;供者:5例(50%)无并发症,4例(40%)为I级,1例为III级。
临床怎么用
- 对于经过选择的、局限于肝脏且不可切除的结直肠癌肝转移患者,可考虑全肝切除加活体供肝移植。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Colorectal cancer is a leading cause of cancer-related death, and nearly 70% of patients with this cancer have unresectable colorectal cancer liver metastases (CRLMs). Compared with chemotherapy, liver transplant has been reported to improve survival in patients with CRLMs, but in North America, liver allograft shortages make the use of deceased-donor allografts for this indication problematic. OBJECTIVE: To examine survival outcomes of living-donor liver transplant (LDLT) for unresectable, liver-confined CRLMs. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included patients at 3 North American liver transplant centers with established LDLT programs, 2 in the US and 1 in Canada. Patients with liver-confined, unresectable CRLMs who had demonstrated sustained disease control on oncologic therapy met the inclusion criteria for LDLT. Patients included in this study underwent an LDLT between July 2017 and October 2020 and were followed up until May 1, 2021. EXPOSURES: Living-donor liver transplant. MAIN OUTCOMES AND MEASURES: Perioperative morbidity and mortality of treated patients and donors, assessed by univariate statistics, and 1.5-year Kaplan-Meier estimates of recurrence-free and overall survival for transplant recipients. RESULTS: Of 91 evaluated patients, 10 (11%) underwent LDLT (6 [60%] male; median age, 45 years [range, 35-58 years]). Among the 10 living donors, 7 (70%) were male, and the median age was 40.5 years (range, 27-50 years). Kaplan-Meier estimates for recurrence-free and overall survival at 1.5 years after LDLT were 62% and 100%, respectively. Perioperative morbidity for both donors and recipients was consistent with established standards (Clavien-Dindo complications among recipients: 3 [10%] had none, 3 [30%] had grade II, and 4 [40%] had grade III; donors: 5 [50%] had none, 4 [40%] had grade I, and 1 had grade III). CONCLUSIONS AND RELEVANCE: This study's findings of recurrence-free and overall survival rates suggest that select patients with unresectable, liver-confined CRLMs may benefit from total hepatectomy and LDLT.
引用
- Hernandez-Alejandro R, Ruffolo LI, Sasaki K, et al. Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases. JAMA Surg. 2022. PMID: 35353121. doi:10.1001/jamasurg.2022.0300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。